Price Alert

Merck & Co. Inc. (MRK)

NYSE: MRK · Real-Time Price · USD

84.12

0.91 (1.09%)

At close: Aug 29, 2025, 3:59 PM

84.13

0.02%

After-hours: Aug 29, 2025, 07:56 PM EDT

1.09% (1D)

Bid	84
Market Cap	210.11B
Revenue (ttm)	63.62B
Net Income (ttm)	16.41B
EPS (ttm)	6.49
PE Ratio (ttm)	12.96
Forward PE	8.73
Analyst	Hold

Ask	84.24
Volume	7,334,244
Avg. Volume (20D)	14,021,285
Open	83.42
Previous Close	83.21
Day's Range	83.28 - 84.24
52-Week Range	73.31 - 120.30
Beta	0.39

About MRK

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MRK

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MRK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Merck & Co. Inc. is scheduled to release its earnings on Oct 30, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-1.7%

Merck & Co shares are trading lower after the comp... Unlock content with Pro Subscription

1 month ago

+2.88%

Merck shares are trading higher after the company announced it will acquire Verona Pharma.

News

1 day ago · seekingalpha.com

Top 10 High-Yield Dividend Stocks For September 2025

My watchlist outperformed SPY and VYM since July 1st, offering higher yield and competitive total returns, despite trailing benchmarks year-to-date. The strategy focuses on high-quality, attractively ...

3 days ago · businesswire.com

Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides New Results for Vericiguat in Patients with Chronic Heart Failure and Reduced Ejection Fraction. Results presented at ESC 2025.

3 days ago · zacks.com

ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?

AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.

4 days ago · zacks.com

Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue?

Merck (MRK) reported earnings 30 days ago. What's next for the stock?

4 days ago · zacks.com

MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate

Merck and Daiichi Sankyo begin dosing in the phase III HERTHENA-Breast04 study on patritumab deruxtecan in certain breast cancer patients.

4 days ago · zacks.com

Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line?

Merck halts Gardasil shipments in China after weak demand hurts sales, with declines also seen in Japan.

6 days ago · benzinga.com

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Summit Therapeutics Inc SMMT and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung c...